Etanercept biosimilar (recombinant human tumor necrosis factor-α receptor II: IgG Fc fusion protein) and methotrexate combination therapy in Chinese patients with moderate-to-severe plaque psoriasis: a multicentre, randomized, double-blind, placebo-controlled trial
Sign Up to like & getrecommendations! Published in 2019 at "Archives of Dermatological Research"
DOI: 10.1007/s00403-019-02024-6
Abstract: Etanercept biosimilar recombinant human tumour necrosis factor-α receptor II: IgG Fc fusion protein (rhTNFR-Fc, trade name Yisaipu) has shown good efficacy in the treatment of moderate-to-severe plaque psoriasis. To compare the efficacy and safety of… read more here.
Keywords: severe plaque; plaque psoriasis; moderate severe; rhtnfr plus ... See more keywords